Увійти

Готові списки джерел за темами / APOQUEL / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: APOQUEL.

Статті в журналах з теми "APOQUEL"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-29 статей у журналах для дослідження на тему "APOQUEL".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Meere, C., and S. Vandenabeele. "Therapeutic complications and follow-up in a dog with atopic dermatitis." Vlaams Diergeneeskundig Tijdschrift 88, no. 3 (2019): 168–74. http://dx.doi.org/10.21825/vdt.v88i3.16022.

Повний текст джерела

Анотація:

In this case report, the therapeutic follow-up of a four-year-old, male, castrated Shih Tzu with atopic dermatitis is described. The treatment first consisted of prednisolone (Prednisolone®), followed by oclacitinib (Apoquel®) and afterwards lokivetmab (Cytopoint®). Furthermore, the diagnosis of AD and the different treatment options are discussed. In addition, more information is given about lokivetmab (Cytopoint®), a new therapeutic agent.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Abramov, S. V., V. V. Golovin, E. A. Tikhonova, and A. V. Balyshev. "Bioequivalence study of veterinary drugs based on oclacitinib «Nicialle» and «Apoquel» in dogs." Agrarian science 1, no. 8 (2023): 22–26. http://dx.doi.org/10.32634/0869-8155-2023-373-8-22-26.

Повний текст джерела

Анотація:

The article presents the results of a study of the comparative pharmacokinetics (bioequivalence) of two drugs for veterinary use-the reproduced drug «Nizialle» and the original drug «Apoquel». The experiments were carried out on 12 dogs divided into two equal groups (six individuals in each). Animals of one group were given a reproduced drug orally, dogs of the other group were given a reference drug. The studied drugs were injected into the body of dogs once (individually) orally. Each animal was given a dose of each drug, corresponding to 0.6 mg oclacitinib per 1 kg of body weight. After a s

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Emmerich, I. U. "Neue Arzneimittel für Kleintiere 2014." Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere 43, no. 03 (2015): 170–80. http://dx.doi.org/10.15654/tpk-150260.

Повний текст джерела

Анотація:

ZusammenfassungIm Jahr 2014 kamen für Kleintiere sechs neue Wirkstoffe auf den deutschen Tierarzneimittelmarkt: Die Ektoparasitika der Isoxazolin-Gruppe Afoxolaner (NexGard®) und Fluralaner (Bravecto®) und das Neonikotinoid Dinotefuran (Vectra 3D, Vectra Felis), das Antidiabetikum Protamin-Zink-Insulin humanen Ursprungs (ProZinc®), das Antimykotikum Ketoconazol (Fugazid®) sowie das Zytostatikum Oclacitinib (Apoquel®). Zwei Wirkstoffe erhielten eine Tierartenerweiterung. So wurden das Antiparasitikum Eprinomectin und das Antibiotikum Clindamycin auch für Katzen zugelassen. Vorgestellt werden fe

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Chupryna, M. I. "Therapeutic effectiveness of different schemes for the associated form of mycosis in dogs." Veterinary Science, Technologies of Animal Husbandry and Nature Management, no. 10 (October 26, 2024): 152–58. https://doi.org/10.31890/vttp.2024.10.14.

Повний текст джерела

Анотація:

Fungal infections are quite common among dogs, and the development of a generalized form of the disease causes severe secondary infections. Today in Ukraine, most dogs are companions that are constantly with the owner, therefore, in some cases, from sick animals with malassezia and alternariosis, the disease spreads to the owners, causing the development of allergic conditions of the skin and respiratory system. The aim of the work was to develop an effective treatment scheme for canine mycosis in an associated form. For this, two therapy schemes have been developed, which involve the complex

Стилі APA, Harvard, Vancouver, ISO та ін.

5

KATANALP, ÖMER FARUK, and AKIN KOÇHAN. "Investigation of the effects of oclacitinib maleate on clinical improvement and serum cytokine levels in dogs with atopic dermatitis." Medycyna Weterynaryjna 80, no. 01 (2024): 6828–2024. http://dx.doi.org/10.21521/mw.6828.

Повний текст джерела

Анотація:

The aim of this study was to present allergens involved in the etiology of atopic dermatitis (AD) in dogs, to determine and classify the clinical severity of the disease using the CADESI-4 and pruritus scores, to investigate changes in serum cytokine levels in dogs with AD and their relationship with clinical findings, and to investigate the effects of oclacitinib maleate on clinical improvement and serum cytokine levels. The material of the study consisted of 20 dogs diagnosed with AD and 10 healthy dogs. CADESI and pVAS scores were obtained from the patients, and blood samples were taken. He

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Drake, Gabby J., Tim Nuttall, Javier López, et al. "TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®)." Journal of Zoo and Wildlife Medicine 48, no. 3 (2017): 818–28. http://dx.doi.org/10.1638/2016-0239.1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Gonzales, A. J., J. W. Bowman, G. J. Fici, M. Zhang, D. W. Mann, and M. Mitton‐Fry. "Oclacitinib ( APOQUEL ® ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy." Journal of Veterinary Pharmacology and Therapeutics 37, no. 4 (2014): 317–24. http://dx.doi.org/10.1111/jvp.12101.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Houtsaeger, C., S. Vandenabeele, and D. Paepe. "De therapeutische opties voor caniene atopische dermatitis: 2010 versus 2015." Vlaams Diergeneeskundig Tijdschrift 89, no. 4 (2020): 191–97. http://dx.doi.org/10.21825/vdt.v89i4.16576.

Повний текст джерела

Анотація:

Alhoewel caniene atopische dermatitis (CAD) de meest voorkomende huidaandoening bij de hond is, is de therapeutische aanpak niet voor de hand liggend. Sinds enkele jaren is er een stijgend inzicht in de pathogenese, wat tot een aangepaste aanpak van CAD en het ontwikkelen van nieuwe therapeutische opties heeft geleid. In de voorliggende studie werden 28 patiënten met CAD in 2010 en 34 patiënten met CAD in 2015 met elkaar vergeleken om de effecten van deze recente adviezen en de komst van een nieuw product in 2014, i.e. Apoquel® (Oclacitinib, Zoetis VSA) te evalueren. Bij de patiënten aangebode

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Popp, Paulina J. C., and Ralf S. Mueller. "Oclacitinib – Januskinase-Hemmung in der Veterinärdermatologie." Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere 53, no. 03 (2025): 146–58. https://doi.org/10.1055/a-2546-1573.

Повний текст джерела

Анотація:

ZusammenfassungOclacitinib (Apoquel, Zoetis) ist aktuell der einzige in der EU für die Veterinärmedizin zugelassene Januskinase (JAK)-Inhibitor. Das Medikament ist zugelassen für die Behandlung von atopischer Dermatitis und allergischem Juckreiz des Hundes. Hierfür wird es bereits seit über 10 Jahren sicher und erfolgreich eingesetzt. Weiterhin sind bereits mehrere Fallberichte publiziert, welche nach Ausschöpfung der zugelassenen Medikamente von einem erfolgreichen Off-Label-Einsatz von Oclacitinib insbesondere bei T-Zell-mediierten Krankheitsbildern berichten.Oclacitinib ist nur für Hunde zu

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Motz, Alyssa K., Lindsay L. St. Germaine, Daniel E. Hoffmann, and Jed Sung. "A retrospective evaluation of the effect of oclacitinib (Apoquel) administration on development of surgical site infection following clean orthopedic stifle surgery." PLOS ONE 18, no. 8 (2023): e0289827. http://dx.doi.org/10.1371/journal.pone.0289827.

Повний текст джерела

Анотація:

The aim of this study was to determine the effect of oclacitinib (Apoquel) on development of surgical site infections in canines following clean orthopedic stifle surgery. Medical records of dogs undergoing unilateral, clean orthopedic stifle procedures were retrospectively examined for development of post-operative surgical site infections. Data collected for statistical analysis included age, sex, body weight, current medications, anesthesia and surgery times, white blood cell count, and neutrophil count. Surgical site infections were identified in 8.7% (34/390) of stifle procedures– 8.0% (2

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Ryman, Emily, Merilyn Dobbs, Leslie Gabor, Abishek Santhakumar, Brian Cassar, and Nidhish Francis. "Comparing Blood Sampling Techniques in Canines: A Pilot Study Using Oclacitinib." Veterinary Sciences 12, no. 6 (2025): 543. https://doi.org/10.3390/vetsci12060543.

Повний текст джерела

Анотація:

Pharmacokinetic studies are critical to assess drug absorption, distribution, metabolism, and excretion in companion animals. Blood collection methods such as direct venepuncture or indwelling catheters could influence pharmacokinetic outcomes and animal welfare. A direct comparison of drug concentrations of two blood sampling methods was investigated in this study to identify any potential differences and their impact on animal welfare. Four canines (male = 3, female = 1) were treated with Apoquel® (oclacitinib 0.4–0.6 mg/kg) and blood samples were obtained via direct venepuncture into the ju

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Tomich, Lara M., and Jason B. Pieper. "Urticaria pigmentosa-like skin disease in a domestic shorthair cat." Journal of Feline Medicine and Surgery Open Reports 5, no. 1 (2019): 205511691882119. http://dx.doi.org/10.1177/2055116918821197.

Повний текст джерела

Анотація:

Case summary A 14-month-old castrated male domestic shorthair cat presented with an 8 month history of severe pruritus, alopecia, papules and excoriations. Initial evaluation and treatment prior to referral included skin scrape, cytology, two strict food trials, dermatophyte culture, and bacterial culture and sensitivity, as well as antibiotic therapy, empiric treatment for mites, steroids and ciclosporin A (Atopica; Elanco). The cat was referred to the Dermatology and Otology Clinic at the University of Illinois Veterinary Teaching Hospital for further diagnostics and treatment. Skin scrapes

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Gadeyne, Caroline, Peter Little, Vickie L. King, Nigel Edwards, Kylie Davis, and Michael R. Stegemann. "Efficacy of oclacitinib (Apoquel ® ) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client‐owned dogs in Australia." Veterinary Dermatology 25, no. 6 (2014): 512. http://dx.doi.org/10.1111/vde.12166.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Yevtushenko, Inna, Dmytro Bilyi, Olesya Tsymerman, and Anastasia Nepochatova. "Clinical manifestation and methods of treatment of pododermatitis in dogs." Scientific Horizons 24, no. 1 (2021): 29–35. http://dx.doi.org/10.48077/scihor.24(1).2021.29-35.

Повний текст джерела

Анотація:

This paper provides data on the clinical signs of pododermatitis in dogs and also investigates effective treatment regimens. The urgency of the stated problem is due to the growing incidence of pododermatitis in dogs, its polyetiological nature, which requires a multifaceted approach to diagnostics and the introduction of effective treatments methods. Thereby, the purpose of the study was to investigate the clinical manifestations of skin diseases of the distal extremities in dogs and to determine the efficacy of complex therapy of pododermatitis. The studies were based on clinical research me

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Visser, Marike, Kelly Walsh, Vickie King, Gordon Sture, and Laura Caneva. "Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis." BMC Veterinary Research 18, no. 1 (2022). http://dx.doi.org/10.1186/s12917-022-03210-x.

Повний текст джерела

Анотація:

Abstract Background The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4–0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States. Results Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and wer

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Damone, James M., Sara Lister, and Bridget M. Lyons. "Oclacitinib (Apoquel) toxicosis resulting in acute kidney injury in a dog." Journal of the American Veterinary Medical Association, June 4, 2025, 1–2. https://doi.org/10.2460/javma.25.04.0240.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Swanson, Leah D., Holly A. Hommerding, Renee D. Schmid, and Lynn R. Hovda. "Multisystemic Consequences Following Oclacitinib Maleate (Apoquel®) Overdose Ingestion in Cats and Dogs." Journal of Medical Toxicology, April 21, 2025. https://doi.org/10.1007/s13181-025-01076-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

"O74 | Population pharmacokinetic modeling and pharmacokinetic simulations of dose scenarios with apoquel® (oclacitinib)." Journal of Veterinary Pharmacology and Therapeutics 46, S1 (2023): 64–65. http://dx.doi.org/10.1111/jvp.13240.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Gotthelf, LN. "Efficacy of APOQUEL® for the Control of Otitis Externa Secondary to Allergic Skin Disease in Client-Owned Dogs." August 30, 2017. https://doi.org/10.19070/2332-2748-1700041.

Повний текст джерела

Анотація:

<strong>Background</strong>: This single-arm, unmasked, single-site study was conducted to evaluate the efficacy of oclacitinib (APOQUEL®) administered twice daily for 14 days with a topical anti-infective, when indicated, for the control of otitis externa secondary to allergic skin disease in dogs. Thirteen (13) client-owned dogs were enrolled; three (3) dogs were withdrawn for owner non-compliance. Dogs were required to be ≥1 year old, weigh 3.0-80.0 kg, have uncomplicated otitis externa that the Investigator attributed to allergic skin disease, have an Otitis Index Score of ≥6 and been with

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Christman, Jane E., Dunbar Gram, James F. X. Wellehan, et al. "THE USE OF INTRADERMAL ALLERGY TESTING FOR ALLERGIC DERMATITIS IN PTEROPID BATS AND TREATMENT WITH ALLERGEN SPECIFIC IMMUNOTHERAPY: A CASE SERIES." Journal of Zoo and Wildlife Medicine 52, no. 4 (2021). https://doi.org/10.5281/zenodo.13477990.

Повний текст джерела

Анотація:

(Uploaded by Plazi for the Bat Literature Project) This case series describes the diagnosis of allergic dermatitis and management with allergenspecific immunotherapy (ASIT) based on intradermal allergy testing (IDAT) and adjunctive medical therapy in six pteropid bats; five large flying foxes (Pteropus vampyrus); and one variable flying fox (Pteropus hypomelanus). The cases ranged from 2 to 15 yr of age at the time of presentation. Clinical signs varied between individuals and included moist ulcerative cutaneous lesions in nonhaired skin, blepharoconjunctivitis, alopecia, and pruritus. All bat

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Christman, Jane E., Dunbar Gram, James F. X. Wellehan, et al. "THE USE OF INTRADERMAL ALLERGY TESTING FOR ALLERGIC DERMATITIS IN PTEROPID BATS AND TREATMENT WITH ALLERGEN SPECIFIC IMMUNOTHERAPY: A CASE SERIES." Journal of Zoo and Wildlife Medicine 52, no. 4 (2021). https://doi.org/10.5281/zenodo.13477990.

Повний текст джерела

Анотація:

(Uploaded by Plazi for the Bat Literature Project) This case series describes the diagnosis of allergic dermatitis and management with allergenspecific immunotherapy (ASIT) based on intradermal allergy testing (IDAT) and adjunctive medical therapy in six pteropid bats; five large flying foxes (Pteropus vampyrus); and one variable flying fox (Pteropus hypomelanus). The cases ranged from 2 to 15 yr of age at the time of presentation. Clinical signs varied between individuals and included moist ulcerative cutaneous lesions in nonhaired skin, blepharoconjunctivitis, alopecia, and pruritus. All bat

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Christman, Jane E., Dunbar Gram, James F. X. Wellehan, et al. "THE USE OF INTRADERMAL ALLERGY TESTING FOR ALLERGIC DERMATITIS IN PTEROPID BATS AND TREATMENT WITH ALLERGEN SPECIFIC IMMUNOTHERAPY: A CASE SERIES." Journal of Zoo and Wildlife Medicine 52, no. 4 (2021). https://doi.org/10.5281/zenodo.13477990.

Повний текст джерела

Анотація:

(Uploaded by Plazi for the Bat Literature Project) This case series describes the diagnosis of allergic dermatitis and management with allergenspecific immunotherapy (ASIT) based on intradermal allergy testing (IDAT) and adjunctive medical therapy in six pteropid bats; five large flying foxes (Pteropus vampyrus); and one variable flying fox (Pteropus hypomelanus). The cases ranged from 2 to 15 yr of age at the time of presentation. Clinical signs varied between individuals and included moist ulcerative cutaneous lesions in nonhaired skin, blepharoconjunctivitis, alopecia, and pruritus. All bat

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Christman, Jane E., Dunbar Gram, James F. X. Wellehan, et al. "THE USE OF INTRADERMAL ALLERGY TESTING FOR ALLERGIC DERMATITIS IN PTEROPID BATS AND TREATMENT WITH ALLERGEN SPECIFIC IMMUNOTHERAPY: A CASE SERIES." Journal of Zoo and Wildlife Medicine 52, no. 4 (2021). https://doi.org/10.5281/zenodo.13477990.

Повний текст джерела

Анотація:

(Uploaded by Plazi for the Bat Literature Project) This case series describes the diagnosis of allergic dermatitis and management with allergenspecific immunotherapy (ASIT) based on intradermal allergy testing (IDAT) and adjunctive medical therapy in six pteropid bats; five large flying foxes (Pteropus vampyrus); and one variable flying fox (Pteropus hypomelanus). The cases ranged from 2 to 15 yr of age at the time of presentation. Clinical signs varied between individuals and included moist ulcerative cutaneous lesions in nonhaired skin, blepharoconjunctivitis, alopecia, and pruritus. All bat

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Christman, Jane E., Dunbar Gram, James F. X. Wellehan, et al. "THE USE OF INTRADERMAL ALLERGY TESTING FOR ALLERGIC DERMATITIS IN PTEROPID BATS AND TREATMENT WITH ALLERGEN SPECIFIC IMMUNOTHERAPY: A CASE SERIES." Journal of Zoo and Wildlife Medicine 52, no. 4 (2021). https://doi.org/10.5281/zenodo.13477990.

Повний текст джерела

Анотація:

(Uploaded by Plazi for the Bat Literature Project) This case series describes the diagnosis of allergic dermatitis and management with allergenspecific immunotherapy (ASIT) based on intradermal allergy testing (IDAT) and adjunctive medical therapy in six pteropid bats; five large flying foxes (Pteropus vampyrus); and one variable flying fox (Pteropus hypomelanus). The cases ranged from 2 to 15 yr of age at the time of presentation. Clinical signs varied between individuals and included moist ulcerative cutaneous lesions in nonhaired skin, blepharoconjunctivitis, alopecia, and pruritus. All bat

Стилі APA, Harvard, Vancouver, ISO та ін.

25

LN, Gotthelf. "Efficacy of APOQUEL® for the Control of Otitis Externa Secondary to Allergic Skin Disease in Client-Owned Dogs." International Journal of Veterinary Health Science & Research, August 30, 2017, 208–12. http://dx.doi.org/10.19070/2332-2748-1700041.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Gonzales, Andrea J., Michelle Aleo, Sean Mahabir, James Messamore, and Michael Stegemann. "Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis." Journal of Veterinary Pharmacology and Therapeutics, June 26, 2024. http://dx.doi.org/10.1111/jvp.13462.

Повний текст джерела

Анотація:

AbstractOclacitinib is a novel Janus kinase (JAK) inhibitor that potently inhibits JAK1‐dependent cytokines involved in allergy, inflammation, and pruritus (IL‐2, IL‐4, IL‐6, IL‐13, and IL‐31). Oclacitinib (Apoquel®, Zoetis Inc, Parsippany, NJ) is approved for the treatment/control of pruritus associated with allergic dermatitis and treatment/control of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. To evaluate the effectiveness of oclacitinib in dogs with flea allergy dermatitis, the JAK1 selective inhibitor was tested in a placebo‐controlled, masked, single‐d

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hernandez‐Bures, Andrea, Wille A. Bidot, Craig E. Griffin, and Wayne S. Rosenkrantz. "The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis." Veterinary Dermatology, September 12, 2023. http://dx.doi.org/10.1111/vde.13203.

Повний текст джерела

Анотація:

AbstractBackgroundOclacitinib (Apoquel; Zoetis) has been reported to be beneficial for treating immune‐mediated disorders.Hypothesis/ObjectivesThis retrospective study evaluates which group is most effective at inducing remission in cases of canine pemphigus foliaceus (PF) with matched induction dosing of glucocorticoids [oclacitinib (OC) group versus azathioprine (AZ) group], and evaluates which group had a higher glucocorticoid‐sparing effect.AnimalsReview of 30 medical records of dogs diagnosed with PF presented to a private practice dermatological service.Materials and MethodsRetrospective

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Fleck, Timothy, Lori Norris, Vickie King, Steven Lesman, and Andrea J. Gonzales. "Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL ‐31‐induced pruritus." Journal of Veterinary Pharmacology and Therapeutics, May 19, 2022. http://dx.doi.org/10.1111/jvp.13065.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Rynhoud, Hester, Catriona Croton, Grace Henry, Erika Meler, Justine S. Gibson, and Ricardo J. Soares Magalhaes. "The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study." BMC Veterinary Research 18, no. 1 (2022). http://dx.doi.org/10.1186/s12917-022-03255-y.

Повний текст джерела

Анотація:

Abstract Background Canine allergic dermatitis is a common diagnosis in veterinary practices which can lead to secondary infections requiring treatment with antimicrobials. A previous study suggested that dogs treated with oclacitinib in an Australian referral hospital required fewer courses of antimicrobial therapy compared to dogs receiving other anti-pruritic treatments. This study aimed to quantify the effect of oclacitinib treatment on the use of antimicrobials and other therapies in general practice veterinary clinics across Australia. A retrospective case-controlled review of patient re

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!